share_log

Vertex Pharmaceuticals | SC TO-T: Third party tender offer statement

Vertex Pharmaceuticals | SC TO-T: Third party tender offer statement

福泰制药 | SC TO-T:要约收购声明
美股SEC公告 ·  04/22 16:17

Moomoo AI 已提取核心信息

Vertex Pharmaceuticals Incorporated (Vertex), through its wholly owned subsidiary Adams Merger Sub, Inc. (Purchaser), has announced the commencement of a tender offer to acquire all issued and outstanding shares of Alpine Immune Sciences, Inc. (Alpine). The offer is set at a purchase price of $65.00 per share, net to the seller in cash, without interest and subject to any applicable tax withholding. The tender offer is the initial step in Vertex's strategy to acquire the entire equity interest in Alpine, with plans to subsequently complete a merger, making Alpine a wholly owned subsidiary of Vertex. The offer is subject to certain conditions, including the minimum tender condition, regulatory approvals, and other customary conditions. Vertex expects to file the necessary notifications...Show More
Vertex Pharmaceuticals Incorporated (Vertex), through its wholly owned subsidiary Adams Merger Sub, Inc. (Purchaser), has announced the commencement of a tender offer to acquire all issued and outstanding shares of Alpine Immune Sciences, Inc. (Alpine). The offer is set at a purchase price of $65.00 per share, net to the seller in cash, without interest and subject to any applicable tax withholding. The tender offer is the initial step in Vertex's strategy to acquire the entire equity interest in Alpine, with plans to subsequently complete a merger, making Alpine a wholly owned subsidiary of Vertex. The offer is subject to certain conditions, including the minimum tender condition, regulatory approvals, and other customary conditions. Vertex expects to file the necessary notifications under the HSR Act and may need to comply with other antitrust laws. The board of directors of Alpine has unanimously recommended that shareholders accept the offer and tender their shares. The tender offer is not subject to any financing condition, as Vertex intends to fund the transaction with its existing cash resources. The offer is expected to expire at one minute past 11:59 P.M., Eastern Time, on May 17, 2024, unless extended or terminated earlier.
Vertex Pharmicals Incorporated(Vertex)通过其全资子公司Adams Merger Sub, Inc.(买方)宣布开始收购阿尔卑斯免疫科学公司(Alpine)所有已发行和流通股份。该报价定为每股65.00美元的收购价,向卖方净收取现金,不含利息,并需缴纳任何适用的预扣税。此次要约是Vertex收购阿尔派全部股权战略的第一步,并计划随后完成合并,使阿尔派成为Vertex的全资子公司。该报价受某些条件的约束,包括最低投标条件、监管批准和其他惯例条件。Vertex预计将根据HSR法案提交必要的通知,并可能需要遵守其他反垄断法。阿尔派董事会一致建议股东接受要约并投标股份。本次要约不受任何融资条件的约束,因为Vertex打算用其现有现金资源为交易提供资金。除非提前延长或终止,否则该优惠预计将在美国东部时间2024年5月17日晚上 11:59 之后的一分钟到期。
Vertex Pharmicals Incorporated(Vertex)通过其全资子公司Adams Merger Sub, Inc.(买方)宣布开始收购阿尔卑斯免疫科学公司(Alpine)所有已发行和流通股份。该报价定为每股65.00美元的收购价,向卖方净收取现金,不含利息,并需缴纳任何适用的预扣税。此次要约是Vertex收购阿尔派全部股权战略的第一步,并计划随后完成合并,使阿尔派成为Vertex的全资子公司。该报价受某些条件的约束,包括最低投标条件、监管批准和其他惯例条件。Vertex预计将根据HSR法案提交必要的通知,并可能需要遵守其他反垄断法。阿尔派董事会一致建议股东接受要约并投标股份。本次要约不受任何融资条件的约束,因为Vertex打算用其现有现金资源为交易提供资金。除非提前延长或终止,否则该优惠预计将在美国东部时间2024年5月17日晚上 11:59 之后的一分钟到期。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息